Description
Thymulin (also known as Facteur Thymique Sérique / FTS) is a defined synthetic nonapeptide originally identified and characterized by Mireille Dardenne, Jean-François Bach, and colleagues at the Hôpital Necker / Paris-Descartes University in the 1970s as a circulating zinc-binding thymic hormone produced by thymic epithelial cells. Unlike the complex Thymalin preparation (a Khavinson-tradition bovine thymus peptide mixture), Thymulin is a single-sequence peptide with the structure pyroGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn (pE-AKSQGGSN) featuring an N-terminal pyroglutamate cyclization. A defining biochemical feature of Thymulin is its zinc dependence — the peptide is biologically inactive in its zinc-free form, with biological activity requiring coordination of a Zn²⁺ ion to the peptide structure. Thymulin has been investigated in academic literature (Dardenne, Bach, Savino, Hadden, and colleagues) for zinc-peptide complex chemistry, thymocyte differentiation marker research, T-lymphocyte signaling endpoints, and comparative thymic peptide hormone research. The compound is used primarily as a research tool for zinc-coordinated peptide pharmacology and structure-activity relationship (SAR) studies of thymic peptide hormones.
Benefits (Research Focus)
• Zinc-peptide complex chemistry — studied for the unique zinc-dependent biological activity of the Zn-FTS complex
• Thymic peptide hormone research — investigated as the defined nonapeptide thymic hormone (vs complex Thymalin preparation)
• Thymocyte differentiation research — explored for T-cell maturation marker expression in thymocyte cell research
• Comparative thymic peptide SAR — examined alongside other thymic peptides (Thymalin, Thymogen, Vilon, TA1) for comparative SAR studies
• Pyroglutamate peptide chemistry — researched for N-terminal pyroglutamate cyclization effects on peptide stability and biological activity
What Researchers Look At
• Zinc-binding affinity and Zn-FTS complex formation kinetics
• T-lymphocyte differentiation markers (CD3, CD4, CD8) in thymocyte cell research
• Comparative pharmacology versus Thymalin complex preparation and synthetic thymic dipeptides (Thymogen, Vilon)
• N-terminal pyroglutamate stability and structural research
• Aged-tissue versus young-tissue model responses in comparative thymic cell research
Quick Specs
• Form: Lyophilized white powder
• Net Peptide Content: 20 mg per vial (COA-verified 25.25mg)
• Quantity: 1 vial
• Appearance: White to off-white lyophilizate
• Reconstitution: Bacteriostatic or sterile water (added by the end researcher; biological activity in research models requires zinc coordination)
• Purity: ≥99% by HPLC (COA-verified 99.796%)
• Identity: MS-verified (per COA)
• Storage: Protect from light
Identity Basics
• Compound: Thymulin (also known as FTS — Facteur Thymique Sérique)
• Synonyms: FTS; Serum Thymic Factor; zinc-thymulin (Zn-FTS, active form); pE-AKSQGGSN
• Class: Synthetic nonapeptide; zinc-binding thymic hormone; defined single-sequence peptide (distinct from complex Thymalin preparation)
• Sequence: pyroGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn (pE-AKSQGGSN) — 9 amino acids with N-terminal pyroglutamate cyclization
• Origin: First characterized by Dardenne, Bach, and colleagues at Hôpital Necker / Paris (1970s)
• Molecular Weight: ~858 g/mol (zinc-free form); zinc-coordinated active form: ~921 g/mol
• CAS: 63958-90-7
⚠️ Disclaimer
- This product is intended for laboratory research use only.
- Not for human or veterinary use.
- Not approved for diagnostic, therapeutic, or medical applications.
- Handle using appropriate laboratory safety procedures and personal protective equipment.
COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.
Janoshik COA — Third-Party Testing
• Thymulin VPeptide Canada — May 4, 2026 (99.796% purity, 25.25mg verified)
